Depletion of BTAF1 inhibits Epithelial-to-mesenchymal Transition via the TGF-β Signal pathway in the osteosarcoma

Abstract

Abstract Osteosarcoma (OS) is one of the most malignant tumors of bone with a poor outcome in children and young adolescents and has a poor response to radiotherapy and chemotherapy.At present, it is urgent to find effective biomarkers to prevent and treat osteosarcoma.The BTAF1 (formerly known as TAFII170/TAF-172 and the human ortholog of Saccharomyces cerevisiae Mot1p),are evolutionarily conserved members of the SNF2-like family of ATPase proteins, and it has never been studied in OS.In this study, we first revealed BTAF1 is significantly upregulated in OS, and its expression level is highly correlated with clinicopathological parameters of OS patients. Our Survival curve analysis demonstrated that BTAF1 is a candidate predictor for predicting patient prognosis.Functional experiment results showed BTAF1 promotes the proliferation of OS cells in vitro.Silencing of BTAF1 reduces the colony-forming ability of U2OS cells in vitro and reduces tumor growth in vivo. Mechanism studies have shown that inhibition of BTAF1 reduces the epithelial-to-mesenchymal transition (EMT) through the TGF-β signaling pathway to inhibit OS progression.In summary, BTAF1 plays a regulatory role in the progression of OS,and it may be a new OS diagnostic marker and prognostic factor, providing new ideas for the treatment of OS.